Ligand Pharmaceuticals (LGND)

• Market cap: $2.17B
• 1 day: -1.70%
• 5 days: 5.64%
• 1 month: 6.50%
• 3 months: 6.51%
• 6 months: -3.77%
• Year to date: 3.76%
• 1 year: 38.31%
• 5 years: 0.91%
• 10 years: 24.61%
• Sector: Healthcare
• Industry: Biotechnology

About: Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Employees: 68

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

16% more repeat investments, than reductions

Existing positions increased: 99 | Existing positions reduced: 85

16% more call options, than puts

Call options by funds: $999K | Put options by funds: $860K

14% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 29

1% more funds holding

Funds holding: 255 [Q4 2024] → 257 (+2) [Q1 2025]

1% more capital invested

Capital invested by funds: $1.95B [Q4 2024] → $1.96B (+$11.1M) [Q1 2025]

0.42% more ownership

Funds ownership: 96.46% [Q4 2024] → 96.89% (+0.42%) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $143 27% upside
• Avg. target: $144 28% upside
• High target: $145 29% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Oppenheimer Trevor Allred	29% upside $145	Outperform Maintained	9 May 2025
Stifel Annabel Samimy	27% upside $143	Buy Initiated	10 Apr 2025